Systemic treatment and primary tumor location in patients with metastatic colorectal cancer

Efstathios Antoniou, Nikolaos Andreatos, Georgios A. Margonis, Apostolos Papalois, Jaeyun Wang, Christos Damaskos, Nikolaos Garmpis, Stefan Buettner, Amar Deshwar, Vasilios Pappas, Matthew J Weiss, Timothy M. Pawlik, Emmanouel Pikoulis

Research output: Contribution to journalReview article

Abstract

Purpose: Tumor location (right-sided vs. left-sided) is known to exert a significant influence on the prognosis of primary colorectal cancer (CRC). Given the genetic continuity between primary and metastatic lesions, we aimed to summarize the existing literature on the prognostic implications of primary tumor site as well as to examine the response to chemotherapy by primary tumor location in patients with metastatic CRC (mCRC). Methods: A structured review of the literature was performed between 6/1/2016-7/1/2016 using the Pubmed database. Original research articles published between 1/1/2000-07/01/2016 were considered eligible. The primary endpoints were overall survival (OS)/ progression free survival (PFS) and response to systemic treatment in patients with mCRC. Results: Eleven studies were included. Tumor site was a strong independent predictor of worse OS/PFS in 9 studies, with right-sided tumors having worse prognosis in all cases. Furthermore, 6 studies demonstrated an inferior response to systemic treatment or worse prognosis following the administration of specific regimens among patients with right-sided cancers. As such, there is significant evidence that right-sided lesions are associated with poor outcomes and resistance to systemic treatment. Conclusion: Consequently, primary tumor location should be a consideration, when the administration of systemic therapy is contemplated in mCRC.

Original languageEnglish (US)
Pages (from-to)1447-1456
Number of pages10
JournalJournal of B.U.ON.
Volume22
Issue number6
StatePublished - Nov 1 2017

Fingerprint

Colorectal Neoplasms
Neoplasms
Therapeutics
Disease-Free Survival
Survival
Patient Rights
PubMed
Databases
Drug Therapy
Research

Keywords

  • Bevacizumab
  • Cetuximab
  • Chemotherapy
  • Colorectal cancer
  • Metastasis

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Antoniou, E., Andreatos, N., Margonis, G. A., Papalois, A., Wang, J., Damaskos, C., ... Pikoulis, E. (2017). Systemic treatment and primary tumor location in patients with metastatic colorectal cancer. Journal of B.U.ON., 22(6), 1447-1456.

Systemic treatment and primary tumor location in patients with metastatic colorectal cancer. / Antoniou, Efstathios; Andreatos, Nikolaos; Margonis, Georgios A.; Papalois, Apostolos; Wang, Jaeyun; Damaskos, Christos; Garmpis, Nikolaos; Buettner, Stefan; Deshwar, Amar; Pappas, Vasilios; Weiss, Matthew J; Pawlik, Timothy M.; Pikoulis, Emmanouel.

In: Journal of B.U.ON., Vol. 22, No. 6, 01.11.2017, p. 1447-1456.

Research output: Contribution to journalReview article

Antoniou, E, Andreatos, N, Margonis, GA, Papalois, A, Wang, J, Damaskos, C, Garmpis, N, Buettner, S, Deshwar, A, Pappas, V, Weiss, MJ, Pawlik, TM & Pikoulis, E 2017, 'Systemic treatment and primary tumor location in patients with metastatic colorectal cancer', Journal of B.U.ON., vol. 22, no. 6, pp. 1447-1456.
Antoniou E, Andreatos N, Margonis GA, Papalois A, Wang J, Damaskos C et al. Systemic treatment and primary tumor location in patients with metastatic colorectal cancer. Journal of B.U.ON. 2017 Nov 1;22(6):1447-1456.
Antoniou, Efstathios ; Andreatos, Nikolaos ; Margonis, Georgios A. ; Papalois, Apostolos ; Wang, Jaeyun ; Damaskos, Christos ; Garmpis, Nikolaos ; Buettner, Stefan ; Deshwar, Amar ; Pappas, Vasilios ; Weiss, Matthew J ; Pawlik, Timothy M. ; Pikoulis, Emmanouel. / Systemic treatment and primary tumor location in patients with metastatic colorectal cancer. In: Journal of B.U.ON. 2017 ; Vol. 22, No. 6. pp. 1447-1456.
@article{9403ddfd029b43439132e4aa92797cb0,
title = "Systemic treatment and primary tumor location in patients with metastatic colorectal cancer",
abstract = "Purpose: Tumor location (right-sided vs. left-sided) is known to exert a significant influence on the prognosis of primary colorectal cancer (CRC). Given the genetic continuity between primary and metastatic lesions, we aimed to summarize the existing literature on the prognostic implications of primary tumor site as well as to examine the response to chemotherapy by primary tumor location in patients with metastatic CRC (mCRC). Methods: A structured review of the literature was performed between 6/1/2016-7/1/2016 using the Pubmed database. Original research articles published between 1/1/2000-07/01/2016 were considered eligible. The primary endpoints were overall survival (OS)/ progression free survival (PFS) and response to systemic treatment in patients with mCRC. Results: Eleven studies were included. Tumor site was a strong independent predictor of worse OS/PFS in 9 studies, with right-sided tumors having worse prognosis in all cases. Furthermore, 6 studies demonstrated an inferior response to systemic treatment or worse prognosis following the administration of specific regimens among patients with right-sided cancers. As such, there is significant evidence that right-sided lesions are associated with poor outcomes and resistance to systemic treatment. Conclusion: Consequently, primary tumor location should be a consideration, when the administration of systemic therapy is contemplated in mCRC.",
keywords = "Bevacizumab, Cetuximab, Chemotherapy, Colorectal cancer, Metastasis",
author = "Efstathios Antoniou and Nikolaos Andreatos and Margonis, {Georgios A.} and Apostolos Papalois and Jaeyun Wang and Christos Damaskos and Nikolaos Garmpis and Stefan Buettner and Amar Deshwar and Vasilios Pappas and Weiss, {Matthew J} and Pawlik, {Timothy M.} and Emmanouel Pikoulis",
year = "2017",
month = "11",
day = "1",
language = "English (US)",
volume = "22",
pages = "1447--1456",
journal = "Journal of B.U.ON.",
issn = "1107-0625",
publisher = "Balkan Union of Oncology",
number = "6",

}

TY - JOUR

T1 - Systemic treatment and primary tumor location in patients with metastatic colorectal cancer

AU - Antoniou, Efstathios

AU - Andreatos, Nikolaos

AU - Margonis, Georgios A.

AU - Papalois, Apostolos

AU - Wang, Jaeyun

AU - Damaskos, Christos

AU - Garmpis, Nikolaos

AU - Buettner, Stefan

AU - Deshwar, Amar

AU - Pappas, Vasilios

AU - Weiss, Matthew J

AU - Pawlik, Timothy M.

AU - Pikoulis, Emmanouel

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Purpose: Tumor location (right-sided vs. left-sided) is known to exert a significant influence on the prognosis of primary colorectal cancer (CRC). Given the genetic continuity between primary and metastatic lesions, we aimed to summarize the existing literature on the prognostic implications of primary tumor site as well as to examine the response to chemotherapy by primary tumor location in patients with metastatic CRC (mCRC). Methods: A structured review of the literature was performed between 6/1/2016-7/1/2016 using the Pubmed database. Original research articles published between 1/1/2000-07/01/2016 were considered eligible. The primary endpoints were overall survival (OS)/ progression free survival (PFS) and response to systemic treatment in patients with mCRC. Results: Eleven studies were included. Tumor site was a strong independent predictor of worse OS/PFS in 9 studies, with right-sided tumors having worse prognosis in all cases. Furthermore, 6 studies demonstrated an inferior response to systemic treatment or worse prognosis following the administration of specific regimens among patients with right-sided cancers. As such, there is significant evidence that right-sided lesions are associated with poor outcomes and resistance to systemic treatment. Conclusion: Consequently, primary tumor location should be a consideration, when the administration of systemic therapy is contemplated in mCRC.

AB - Purpose: Tumor location (right-sided vs. left-sided) is known to exert a significant influence on the prognosis of primary colorectal cancer (CRC). Given the genetic continuity between primary and metastatic lesions, we aimed to summarize the existing literature on the prognostic implications of primary tumor site as well as to examine the response to chemotherapy by primary tumor location in patients with metastatic CRC (mCRC). Methods: A structured review of the literature was performed between 6/1/2016-7/1/2016 using the Pubmed database. Original research articles published between 1/1/2000-07/01/2016 were considered eligible. The primary endpoints were overall survival (OS)/ progression free survival (PFS) and response to systemic treatment in patients with mCRC. Results: Eleven studies were included. Tumor site was a strong independent predictor of worse OS/PFS in 9 studies, with right-sided tumors having worse prognosis in all cases. Furthermore, 6 studies demonstrated an inferior response to systemic treatment or worse prognosis following the administration of specific regimens among patients with right-sided cancers. As such, there is significant evidence that right-sided lesions are associated with poor outcomes and resistance to systemic treatment. Conclusion: Consequently, primary tumor location should be a consideration, when the administration of systemic therapy is contemplated in mCRC.

KW - Bevacizumab

KW - Cetuximab

KW - Chemotherapy

KW - Colorectal cancer

KW - Metastasis

UR - http://www.scopus.com/inward/record.url?scp=85045696573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045696573&partnerID=8YFLogxK

M3 - Review article

C2 - 29332337

AN - SCOPUS:85045696573

VL - 22

SP - 1447

EP - 1456

JO - Journal of B.U.ON.

JF - Journal of B.U.ON.

SN - 1107-0625

IS - 6

ER -